ArticleFrontiers in physiology2026
The attenuated incretin effect is associated with glucose intolerance in patients with hepatitis B-related acute-on-chronic liver failure.
Article in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The pathogenesis of glucose homeostasis disturbance in acute-on-chronic liver failure (ACLF) remains poorly defined. This study aimed to investigate the association between incretin effect (IE) and glucose intolerance in patients with hepatitis B virus-related ACLF (HBV-ACLF). Methods: In this prospective study, 25 patients with HBV-ACLF were stratified by glucose tolerance: normal glucose tolerance (NGT, n=7), pre-diabetes (pre-DM, n=9), and diabetes mellitus (DM, n=9). All participants underwent paired oral (OGTT) and intravenous glucose tolerance test (IVGTT) within 72 hours of admission. Dynamic profiles of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and insulin were analyzed. The IE, calculated from insulin area under the curve (AUC) differences, was compared across groups. Results: Patients with pre-DM and DM exhibited significantly reduced insulin sensitivity and early-phase insulin secretion, alongside elevated insulin resistance, compared to the NGT group. While GLP-1 and GIP responses post-OGTT remained significantly higher than post-IVGTT across all groups, the GIP secretory response was markedly blunted in DM patients compared to those with NGT. Critically, the incremental insulin response during OGTT versus IVGTT was abolished in DM patients but preserved in pre-DM and NGT. Consequently, IE was progressively and significantly reduced from NGT (58.5 ± 9.2%) to pre-DM (44.5 ± 7.5%) to DM (25.8 ± 8.7%) ( Conclusion: The attenuated IE is associated with the severity of glucose intolerance, and the development of DM is associated with a blunted GIP secretory response in patients with HBV-ACLF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.